A Pilot Presurgical Study of Daratumumab (CD38 Antagonist) or JNJ-40346527 in Men With High-Risk Localized Prostate Cancer Followed by Radical Prostatectomy

Trial Profile

A Pilot Presurgical Study of Daratumumab (CD38 Antagonist) or JNJ-40346527 in Men With High-Risk Localized Prostate Cancer Followed by Radical Prostatectomy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2018

At a glance

  • Drugs Daratumumab (Primary) ; PRV-6527 (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Jun 2018 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
    • 26 Jun 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2020.
    • 04 May 2018 A drug has been added(JNJ-40346527 or PRV-6527); Study design changed from single group assignment to parallel; number of arms changed from 1 to 2; planned number of patients changed from 15 to 30.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top